ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,113.75
0.70%
US Tech 100
21,194.72
1.30%
다우존스 지수
44,939.96
0.13%
Bitcoin
104,795.78
0.06%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Immunome Inc (IMNM) 시세

Immunome Inc

Immunome Inc (IMNM)

NASDAQ
11.12
0.61
( 5.80% )
업데이트: 02:09:59
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
11.12
매수가
11.10
매도가
11.14
거래량
683,858
10.50 일간 변동폭 11.24
8.97 52주 범위 30.958
market_cap
694.075M
전일 종가
10.51
개장가
10.54
최근 거래 시간
27
@
11.125
마지막 거래 시간
02:09:59
재정 규모
US$ 7,466,718
VWAP
10.9185
평균 볼륨(3m)
933,311
발행 주식
62,416,845
배당수익률
-
주가수익률
-6.46
주당순이익(EPS)
-1.71
매출
14.02M
순이익
-106.81M

Immunome Inc 정보

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious... Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.immunome.com
본부
Wilmington, Delaware, USA
설립됨
-
Immunome Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker IMNM. The last closing price for Immunome was US$10.51. Over the last year, Immunome shares have traded in a share price range of US$ 8.97 to US$ 30.958.

Immunome currently has 62,416,845 shares in issue. The market capitalisation of Immunome is US$656 million. Immunome has a price to earnings ratio (PE ratio) of -6.46.

IMNM 최신 뉴스

추가 뉴스

Form 8-K - Current report

20 시간 전
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

20 시간 전
Edgar (US Regulatory)

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an...

30 1월 2025
Business Wire

Form 424B5 - Prospectus [Rule 424(b)(5)]

30 1월 2025
Edgar (US Regulatory)

Immunome Announces Proposed Public Offering of Common Stock

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an...

30 1월 2025
Business Wire

Form 8-K - Current report

30 1월 2025
Edgar (US Regulatory)

Form 8-K - Current report

24 1월 2025
Edgar (US Regulatory)

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Immunome to present at the 43rd Annual J.P. Morgan Healthcare Conference. Topline data for Phase 3 RINGSIDE study of varegacestat (formerly known as AL102) expected in second half of 2025. IND...

13 1월 2025
Business Wire

Hummingbird Bioscience Licenses Novel Antibodies to Immunome

SAN FRANCISCO and SINGAPORE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat...

07 1월 2025
GlobeNewswire Inc.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on January 2, 2025...

03 1월 2025
Business Wire
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.827.9611650485410.311.249.06135870110.24276416CS
40.494.6095954844810.6311.69.0690089910.26497764CS
12-1.7754-13.767700110112.895415.1258.9793331111.07910676CS
26-4.51-28.854766474715.6316.738.9775405512.31714206CS
52-6.88-38.22222222221830.9588.9781447215.00266683CS
156336.94581280798.1230.9582.0934066813.58690096CS
260-4.54-28.991060025515.6663.782.0929621615.3999826CS

IMNM - Frequently Asked Questions (FAQ)

What is the current Immunome share price?
The current share price of Immunome is US$ 11.12
How many Immunome shares are in issue?
Immunome has 62,416,845 shares in issue
What is the market cap of Immunome?
The market capitalisation of Immunome is USD 656M
What is the 1 year trading range for Immunome share price?
Immunome has traded in the range of US$ 8.97 to US$ 30.958 during the past year
What is the PE ratio of Immunome?
The price to earnings ratio of Immunome is -6.46
What is the cash to sales ratio of Immunome?
The cash to sales ratio of Immunome is 49.2
What is the reporting currency for Immunome?
Immunome reports financial results in USD
What is the latest annual turnover for Immunome?
The latest annual turnover of Immunome is USD 14.02M
What is the latest annual profit for Immunome?
The latest annual profit of Immunome is USD -106.81M
What is the registered address of Immunome?
The registered address for Immunome is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Immunome website address?
The website address for Immunome is www.immunome.com
Which industry sector does Immunome operate in?
Immunome operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
TCTMTCTM Kids IT Education Inc
US$ 0.81779
(351.57%)
563.45M
BAOSBaosheng Media Group Holdings Ltd
US$ 5.22
(68.39%)
1.73M
REBNReborn Coffee Inc
US$ 3.24
(59.61%)
36.08M
CYCNCyclerion Therapeutics Inc
US$ 3.8602
(51.98%)
59.38M
HUBCWHub Cyber Security Ltd
US$ 0.0491
(46.13%)
124.04k
ENVBEnveric Biosciences Inc
US$ 2.092
(-46.36%)
1.11M
BHILBenson Hill Inc
US$ 2.32
(-41.27%)
2.01M
NIVFNewGenIvf Group Ltd
US$ 0.153
(-40.93%)
10.24M
SHOTWSafety Shot Inc
US$ 0.11
(-26.12%)
103
SPGCSacks Parente Golf Inc
US$ 0.6796
(-24.61%)
4.37M
TCTMTCTM Kids IT Education Inc
US$ 0.8164
(350.80%)
563.46M
RIMEAlgorhythm Holdings Inc
US$ 0.0292
(19.67%)
251.22M
NVDANVIDIA Corporation
US$ 124.98
(0.26%)
169.32M
CLEUChina Liberal Education Holdings Ltd
US$ 0.1617
(9.11%)
126.76M
RGTIRigetti Computing Inc
US$ 13.83
(12.44%)
111.04M

IMNM Discussion

게시물 보기
tw0122 tw0122 2 월 전
Looking good in some reverse head and shoulders at .85+4% and  .92-.99 up next. The world of DNA
👍️0
Monksdream Monksdream 5 월 전
IMNM under $15

👍️0
Monksdream Monksdream 10 월 전
IMNM 10Q due 3/22
👍️0
Monksdream Monksdream 11 월 전
IMNM new 52 week hi
👍️0
Monksdream Monksdream 1 년 전
IMNM new 52 week high
👍️0
OncoJock OncoJock 1 년 전
Agree.

Wish there were most posts on this board.

Wondering who might be the next big customer to sign a major discovery and commercialization contract with IMNM, after AbbVie?

Also wondering if IMNM is doing any discovery/testing/research related to bispecific antibodies, as opposed to antibody-drug conjugates. Bispecifics are HOT HOT HOT in lymphoma and myeloma.

-- OJ
👍️0
OncoJock OncoJock 1 년 전
agree
👍️0
Laster Laster 1 년 전
Hopefully the vote passed.
I think this biotech combined company can be a huge success.
Siegall has proven he can build a biotech company.
This will be fun to watch.
👍️ 1
Laster Laster 1 년 전
I believe merger news tomorrow along with huge financing.
Clay B. Siegall To become chairman and CEO of combined company.
He founded Seagen which just sold for $40 billion to Pfizer.
Their innovative technology from Professor Philip S. Low (Purdue University).
Look at Professor Low accomplishments. Unreal.
Watching closely because this might become a huge biotech company.
👍️ 1
wiwineguy wiwineguy 2 년 전
Ha, sold in fall of 21 for $25.
👍️0
makinezmoney makinezmoney 2 년 전
$IMNM: Now 10.40 !!!!!!!!!!!

Booooooooooooyakashaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa


Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies



GO $IMNM
👍️0
makinezmoney makinezmoney 2 년 전
$IMNM: Boooommmmmmmmmmmmmmm.......now $8.50


Offfffffffffff she goes.

Nice boomer



GO $IMNM
👍️0
Awl416 Awl416 2 년 전
Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies
👍️ 1
wiwineguy wiwineguy 4 년 전
you don't know crap majorbankz. you keep saying i "heard" this, and I "heard" that. can you be any more vague. stfu
👍️0
Harbor6460 Harbor6460 4 년 전
They cannot dilute on the bid. Only the ask
👍️0
Pedro2004 Pedro2004 4 년 전
Pulled down to under $20.00
👍️0
Pedro2004 Pedro2004 4 년 전
They pulled this down to under $21.00

I'm back-in at $21.00
👍️0
Major_Bankz Major_Bankz 4 년 전
$22.50 U worry too much, should be $25+ this afternoon IMO
👍️0
Pedro2004 Pedro2004 4 년 전
I thought this was going to break today. But it' just jumped over $22 -- let's see if that holds.
👍️0
Pedro2004 Pedro2004 4 년 전
This run could have broke $30 today. But the company killed-it.
👍️0
Major_Bankz Major_Bankz 4 년 전
yep, shorties portfolio will get destroyed here.
👍️0
Pedro2004 Pedro2004 4 년 전
The dilution is going to kill this run.
👍️0
Pedro2004 Pedro2004 4 년 전
Looks like the company is dumping shares on the bid.
👍️0
Major_Bankz Major_Bankz 4 년 전
I don't think PFE and MRNA can claim the same effectiveness for DELTA, plus time to buy is during development not after just like when MRNA was at $20. IMO
👍️0
Major_Bankz Major_Bankz 4 년 전
Delta is a BIG problem, IMNM may catch up to PFE and MRNA. IMO
👍️0
Major_Bankz Major_Bankz 4 년 전
Immunome was awarded a $17.6 million technology award from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, to support Immunome’s COVID program.

Given the near-term potential for a resurgence of COVID-19 infections driven by emerging variants, Immunome intends to explore opportunities to expedite the development of this potential therapeutic. The Company plans to submit an IND application with the U.S. Food and Drug Administration (FDA) this quarter.
👍️0
Major_Bankz Major_Bankz 4 년 전
IMNM $21 Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing
👍️0

최근 히스토리

NASDAQ
IMNM
Immunome
NASDAQ
CBPYX
Ci Canadian Balanced Cor...
BIT
SCBA5S
Societe Generale Effekten
NASDAQ
ABJXXXX
Jpmorgan Chase Financial...
LSE
0NSG
Akola Group Ab
NASDAQ
NXTD
NXT ID
BMF
AFSG25
AFSG25 - Fevereiro 2025
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지